Pathology: mUC - L2 - all population; mUC - L2 - PDL1 positive;
mUC - L2 - all population | mUC - L2 - PDL1 positive | |||||
IMvigor-211 (all population), 2018 | KEYNOTE-045 (all population), 2017 | IMvigor-211 (PDL1>5%), 2018 | IMvigor-211 (PDL1>1%), 2018 | KEYNOTE-045 (PDL1 CPS >10%), 2017 | ||
atezolizumab alone | 3 | T1 | T1 | T1 | ||
pembrolizumab alone | 2 | T1 | T1 | |||
Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 | T0 |